Literature DB >> 24421433

Drug monographs: dabrafenib and trametinib.

J Aubrey Waddell, Dominic A Solimando.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@aol.comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2013        PMID： 24421433      PMCID： PMC3859275          DOI： 10.1310/hpj4810-818

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  8 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

2.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Authors:  Jeffrey R Infante; Leslie A Fecher; Gerald S Falchook; Sujatha Nallapareddy; Michael S Gordon; Carlos Becerra; Douglas J DeMarini; Donna S Cox; Yanmei Xu; Shannon R Morris; Vijay G R Peddareddigari; Ngocdiep T Le; Lowell Hart; Johanna C Bendell; Gail Eckhardt; Razelle Kurzrock; Keith Flaherty; Howard A Burris; Wells A Messersmith
Journal:  Lancet Oncol       Date:  2012-07-16       Impact factor: 41.316

3.  Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

Authors:  Gerald S Falchook; Karl D Lewis; Jeffrey R Infante; Michael S Gordon; Nicholas J Vogelzang; Douglas J DeMarini; Peng Sun; Christopher Moy; Stephen A Szabo; Lori T Roadcap; Vijay G R Peddareddigari; Peter F Lebowitz; Ngocdiep T Le; Howard A Burris; Wells A Messersmith; Peter J O'Dwyer; Kevin B Kim; Keith Flaherty; Johanna C Bendell; Rene Gonzalez; Razelle Kurzrock; Leslie A Fecher
Journal:  Lancet Oncol       Date:  2012-07-16       Impact factor: 41.316

4.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman
Journal:  Lancet       Date:  2012-06-25       Impact factor: 79.321

5.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

Authors:  Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascierto; Paul B Chapman; Igor Puzanov; Axel Hauschild; Caroline Robert; Alain Algazi; Laurent Mortier; Hussein Tawbi; Tabea Wilhelm; Lisa Zimmer; Julie Switzky; Suzanne Swann; Anne-Marie Martin; Mary Guckert; Vicki Goodman; Michael Streit; John M Kirkwood; Dirk Schadendorf
Journal:  Lancet Oncol       Date:  2012-10-08       Impact factor: 41.316

6.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

7.  Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Authors:  Gerald S Falchook; Georgina V Long; Razelle Kurzrock; Kevin B Kim; Tobias H Arkenau; Michael P Brown; Omid Hamid; Jeffrey R Infante; Michael Millward; Anna C Pavlick; Steven J O'Day; Samuel C Blackman; C Martin Curtis; Peter Lebowitz; Bo Ma; Daniele Ouellet; Richard F Kefford
Journal:  Lancet       Date:  2012-05-19       Impact factor: 79.321

8.  Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

Authors:  Kevin B Kim; Richard Kefford; Anna C Pavlick; Jeffrey R Infante; Antoni Ribas; Jeffrey A Sosman; Leslie A Fecher; Michael Millward; Grant A McArthur; Patrick Hwu; Rene Gonzalez; Patrick A Ott; Georgina V Long; Olivia S Gardner; Daniele Ouellet; Yanmei Xu; Douglas J DeMarini; Ngocdiep T Le; Kiran Patel; Karl D Lewis
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544
  8 in total
  2 in total

1.  A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer.

Authors:  Ulrike Pfohl; Jürgen Loskutov; Sanum Bashir; Ralf Kühn; Patrick Herter; Markus Templin; Soulafa Mamlouk; Sergei Belanov; Michael Linnebacher; Florian Bürtin; Marcus Vetter; Christoph Reinhard; Lena Wedeken; Christian R A Regenbrecht
Journal:  Cancers (Basel)       Date:  2022-07-01       Impact factor: 6.575

2.  Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma.

Authors:  Devin C Flaherty; Brianna W Hoffner; Briana J Lau; Omid Hamid; Mark B Faries
Journal:  J Surg Oncol       Date:  2015-10-26       Impact factor: 3.454
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.